Current and future drug treatments for the management of osteoporosis

Pharmaceutical Journal

Volumn 284, Issue 7596, 2010, Pages 345-346

  Baqir, Wasim ^a   Copeland, Carmel ^b  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

^b NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; DENOSUMAB; DROLOXIFENE; ERGOCALCIFEROL; LASOFOXIFENE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE REMODELING; CLINICAL TRIAL; DIARRHEA; ESOPHAGUS ULCER; ESTROGEN DEFICIENCY; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STRESS FRACTURE; VEIN THROMBOSIS; VERTEBRA FRACTURE;

EID: 77956168216     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Poór G, Jacobsen SJ, Melton LJ III. Mortality following hip fracture. In:Vellas BJ, Albarede JL, Garry PJ, editors. Facts and research in gerontology.Paris: Serdi; 1994. Pp91-169.
2. National Osteoporosis Guideline Group. Osteoporosis: clinical guideline for prevention and treatment. 2008. Available at www.shef.ac.uk (accessed 1 April 2010).
3. National Institute for Health for Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 160.2008. Available at www.nice.org.uk (accessed 1 April 2010).
4. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 161. 2008. Available at www.nice.org.uk/Guidance/ TA161 (accessed 1 April 2010).
5. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (randomised evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. The Lancet 2005;365:1621-8.
6. MacLean C, Alexander A, Carter J, Chen S, Desai SB, Grossman J, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of Internal Medicine 2008;148:197-213.
7. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M. Upper gastrointestinal tract safety profile of alendronate. The fracture intervention trial. Archives of Internal Medicine 2000;160:517-25.
8. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women Osteoporosis International 2006;17:922-8.
9. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al. Strontium ranelate reduces the risk of non-vertebral fractures in post-menopausal women with osteoporosis: TROPOS study. Journal of Clinical Endocrinology and Metabolism 2005;90:2816-22.
10. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TDet al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New England Journal of Medicine 2004;350:459-68.
11. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
12. Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL et al. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. Journal of Clinical Endocrinology and Metabolism 2009;94:2284-9.
13. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM et al. Lasofoxifene in postmenopausal women with osteoporosis New England Journal of Medicine 2010;362:686-96.
14. Clinical Knowledge Summaries. Osteoporosis treatment. Available at cks.library.nhs.uk (accessed 12 January 2010).
15. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcified Tissue International 2004;74:103-6.
16. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effects of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 2001;16:348-60.
17. Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget's disease. New England Journal of Medicine 2005;353:918-23.
18. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y et al. Two-year treatment with denosumab (AMG 162) in a randomised phase 2 study of postmenopausal women with low BMD. Journal of Bone and Mineral Research 2007;22:1832-41.
19. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomised, blinded, phase 3 trial. Journal of Bone and Mineral Research 2009;24:153-161.
20. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2008;93:2149-57.
21. Cummings SR, San Martin J, McClung M, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in post-menopausal women. New England Journal of Medicine 2009;361:756-65.
22. Stoch SA, Wagner JA. Cathepsin K Inhibitors: a novel target for osteoporosis therapy. Clinical Pharmacology and Therapeutics 2008;83:172-6.